Literature DB >> 9708663

Effect of clonidine on heart rate variability in congestive heart failure.

I Girgis1, S Chakko, E de Marchena, C Jara, P Diaz, A Castellanos, R J Myerburg.   

Abstract

In patients with congestive heart failure, abnormal heart rate variability is a predictor of total mortality and sudden cardiac death. Drugs that improve heart rate variability may have a potential role for improving the survival among these patients. The effects of clonidine were studied in 24 patients with congestive heart failure, sinus rhythm, a left ventricular ejection fraction <0.40, and systolic blood pressure > 115 mm Hg. A 6-minute corridor walk test and 24-hour Holter monitoring were performed before and 42+/-24 days after initiation of clonidine therapy (Catapres-TTS patch, mean dose: 0.33+/-0.21 mg). Changes in other medications used at baseline were not allowed. One patient died suddenly. Two patients did not complete the protocol due to worsening congestive heart failure, which required changes in medications, 1 patient discontinued due to hypotension, and 2 for personal reasons. Among the 18 patients who completed the protocol, the mean RR interval of sinus beats increased from 760+/-106 to 822+/-125 ms (p=0.001) and the distance covered during the 6-minute walk test increased from 1,148+/-277 to 1,255+/-359 feet (p=0.042). Systolic blood pressure decreased from 139+/-15 to 119+/-10 mm Hg (p <0.0001). The following increases were noted in the heart rate variability measurements: high-frequency power in 0.15 to 0.40 Hz: 4.58+/-1.07 to 4.94+/-1.17 In (ms), p=0.002; SD: 47.0+/-16.9 to 52.5+/-18.4 ms, p=0.034; SD of the mean of all RR intervals in 24 hours: 116+/-94 to 130+/-19 ms, p=0.033; SD of all 5-minute mean RR intervals: 106+/-44 to 124+/-66 ms, p=0.042; root-mean square of difference of successive RR intervals: 28.8+/-10.7 to 34.1+/-14.2 ms, p=0.017. Clonidine improves heart rate variability in the patients with congestive heart failure by increasing the parasympathetic tone. It is well tolerated by most patients with heart failure and may have a beneficial effect on exercise capacity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708663     DOI: 10.1016/s0002-9149(98)00329-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Pharmacologic modulation of parasympathetic activity in heart failure.

Authors:  Monali Y Desai; Mari A Watanabe; Abhay A Laddu; Paul J Hauptman
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

2.  Alpha-adrenoceptor gene variants and autonomic nervous system function in a young healthy Japanese population.

Authors:  Tetsuro Matsunaga; Koichiro Yasuda; Tetsuya Adachi; Ning Gu; Tsubasa Yamamura; Toshio Moritani; Gozoh Tsujimoto; Kinsuke Tsuda
Journal:  J Hum Genet       Date:  2006-10-31       Impact factor: 3.172

3.  Muscarinic 2 receptors modulate cardiac proteasome function in a protein kinase G-dependent manner.

Authors:  Mark J Ranek; Curtis K Kost; Chengjun Hu; Douglas S Martin; Xuejun Wang
Journal:  J Mol Cell Cardiol       Date:  2014-02-05       Impact factor: 5.000

Review 4.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.